Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tommy Rampling

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
The Lancet. Infectious Diseases|February 11, 2023
Use of cidofovir in a patient with severe mpox and uncontrolled HIV infectionAdam Stafford, Stephanie Rimmer, Mark Gilchrist, et al.
The Lancet. Infectious Diseases|April 15, 2021
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort studyDan Frampton, Tommy Rampling, Aidan Cross, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
BMJ Open|October 6, 2020
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysisNick G Cunniffe, Simon J Gunter, Michael Brown, et al.
Cell Reports|April 4, 2019
Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated HumansPramila Rijal, Sean C Elias, Samara Rosendo Machado, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The Lancet. Infectious Diseases|December 25, 2022
Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort studyDouglas L Fink, Helen Callaby, Akish Luintel, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
The Lancet. Infectious Diseases|February 11, 2023
Use of cidofovir in a patient with severe mpox and uncontrolled HIV infectionAdam Stafford, Stephanie Rimmer, Mark Gilchrist, et al.
The Lancet. Infectious Diseases|April 15, 2021
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort studyDan Frampton, Tommy Rampling, Aidan Cross, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
BMJ Open|October 6, 2020
How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysisNick G Cunniffe, Simon J Gunter, Michael Brown, et al.
Cell Reports|April 4, 2019
Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated HumansPramila Rijal, Sean C Elias, Samara Rosendo Machado, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The Lancet. Infectious Diseases|December 25, 2022
Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort studyDouglas L Fink, Helen Callaby, Akish Luintel, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Pageof 5